Principles of Wilms' tumor biology

Urologic Clinics of North America

Volumn 27, Issue 3, 2000, Pages 423-434

  Coppes, Max J ^a   Pritchard Jones, Kathy ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME 11P; CHROMOSOME 16Q; GENE MUTATION; HUMAN; NEPHROBLASTOMA; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY;

EID: 0033849353     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0094-0143(05)70090-2     Document Type: Review

References (101)

1. Identification of novel regions of deletion in familial Wilms' tumor by comparative genomic hybridization
2. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome
3. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome
4. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations
5. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
6. Precursor lesions of Wilms tumor: Clinical and biological implications
7. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor
8. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
9. Epidemiologic features of Wilms tumor
10. Genetics and epidemiology of Wilms' tumor: The French Wilms' tumor study
11. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts
12. Age distribution of Wilms' tumor: Report from the National Wilms' Tumor Study
13. Epidemiology of Wilms tumor
14. Epidemiological features of Wilms' tumor: Results of the National Wilms' Tumor Study
15. Germline intronic and exonic mutations in the Wilms' tumor gene (WT1) affecting urogenital development
16. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development
17. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
18. Chromosome 11p15.5 regional imprinting: Comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors
19. A general theory of carcinogenesis
20. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination
21. The role of WT1 in Wilms tumorigenesis
22. Denys-Drash syndrome: Relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1
23. Inherited WT1 mutation in Denys-Drash syndrome
24. Homozygous somatic WT1 point mutations in sporadic unilateral Wilms tumor
25. The path to progress in medical science: A Wilms tumor conspectus
26. Structural rearrangements of the WT1 gene in Wilms' tumour cells
27. Risk of cancer during the first four years of life in children from The Beck-with-Wiedemann Syndrome Registry
28. Constitutional WT1 mutations in Wilms' tumor patients
29. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
30. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1
31. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
32. The role of preoperative chemotherapy in the treatment of nephroblastoma: The SIOP experience. Societe Internationale d'Oncologie Pediatrique
33. Future directions in clinical research in Wilms tumor
34. Wilms tumor
35. Molecular basis of Wilms' tumor
36. Familial pre-disposition to Wilms' tumour does not map to the short arm of chromosome 11
37. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome
38. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
39. The genetics of Wilms' tumor
40. Alternative splicing and genomic structure of the Wilms tumor gene WT1
41. Genomic imprinting: Review and relevance to human diseases
42. Tumour suppressor activity of H19 RNA
43. The genetics of Wilms' tumor - A case of disrupted development
44. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors
45. Functional inactivation of genes by dominant negative mutations
46. p53 Mutations in human cancers
47. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor
48. Evidence for genetic heterogeneity in familial Wilms' tumor
49. Lack of linkage of familial Wilms' tumour to chromosomal band 11p13
50. Evidence for WT1 as a Wilms' tumor (WT) gene: Intragenic germinal deletion in bilateral WT
51. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor
52. Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome)
53. Mutation and cancer: A model for Wilms' tumor of the kidney
54. Mutation and cancer: Statistical study of retinoblastoma
55. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11
56. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5
57. Gene targeting in kidney development
58. WT-1 is required for early kidney development
59. Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours
60. The p53 tumour suppressor gene
61. Zinc finger point mutations within the WT1 gene in Wilms tumor patients
62. Transcriptional repression mediated by the WT1 Wilms tumor gene product
63. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor
64. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11
65. Physical association and functional interaction between the Wilms tumor (WT1) and p53 gene products
66. Cancer susceptibility: Family studies of retinoblastoma and Wilms tumor
67. Genetics of Wilms' tumor
68. A third Wilms' tumor locus on chromosome 16q
69. Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors
70. Relation between cancer and congenital malformations: The value of small series, with a note on pineal tumors in native and migrant Japanese
71. Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors
72. RNA expression of the WT1 gene in Wilms' tumors in relation to histology
73. YAC complementation shows a requirement for WT1 in the development of epicardium, adrenal gland, and throughout nephrogenesis
74. New insights reveal complex mechanisms involved in genomic imprinting
75. Mutations in the p53 gene occur in diverse human tumor types
76. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour
77. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms tumour
78. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
79. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour
80. Expression of the Wilms' tumor gene WT1 in the murine urogenital system
81. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15
82. The candidate Wilms' tumour gene is involved in genitourinary development
83. Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1
84. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21
85. Relaxation of imprinted genes in human cancer
86. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor
87. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p Interstitial deletion
88. Constitutional and acquired rearrangements of chromosome 7 in Wilms tumor
89. Constitutional mosaic t(2;7)(q33;p2) and other rearrangements in a girl with Wilms' tumor
90. Genomic instability in 1p and human malignancies
91. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues
92. Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor
93. Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus
94. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region
95. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11
96. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene
97. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome
98. Germline and somatic abnormalities of chromosome 7 in Wilms' tumor
99. Coordinate expression of Wilms' tumor genes correlates with Wilms' tumor phenotypes
100. Imprinting of human H19: Allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching